Cover Image
市場調查報告書

化療誘發性末梢神經病變:開發中產品分析

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245976
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
Back to Top
化療誘發性末梢神經病變:開發中產品分析 Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 128 Pages
簡介

化學療法引發末梢神經病變 (CIPN)是治療癌症時副作用的一種。主要的症狀有疼痛和加熱感,刺痛,便秘,肌肉無力,血壓的變動,平衡感喪失等。主要的風險要素有長期化治療,及以前便患病的神經症,化療用的醫藥品種類等。

本報告提供全球各國治療化療誘發性末梢神經病變所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

化療誘發性末梢神經病變概要

治療藥的開發

  • 化療誘發性末梢神經病變開發中產品:概要
  • 化療誘發性末梢神經病變開發中產品:比較分析

各企業開發中的化療誘發性末梢神經病變治療藥

大學/研究機關研究中的化療誘發性末梢神經病變治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

化療誘發性末梢神經病變治療藥:開發中的產品一覽 (各企業)

化療誘發性末梢神經病變治療藥:研究中的產品一覽 (大學/研究機關別)

化療誘發性末梢神經病變開發治療藥的企業

  • DARA BioSciences, Inc.
  • DermaXon, LLC
  • Eisai
  • Immune Pharmaceuticals Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • MAKScientific, LLC
  • Mertiva AB
  • Panacea Pharmaceuticals, Inc.
  • PharmatrophiX, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Spinifex Pharmaceuticals Pty Limited
  • Virobay Inc.

化療誘發性末梢神經病變:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • amitoripuchirin+鹽酸Ketamine(K他命)
    • 產品概要
    • 功能機制
    • 研究開發 (R&D) 的發展情形
  • AL-309
  • AM-1710
  • 疼痛治療藥
  • DX-0332
  • E-2072
  • E-52862
  • EMA-401
  • 化療誘發性末梢神經病變遺傳基因療法
  • ketoprofen
  • KRN-5500
  • LM11A-31
  • PAN-811
  • PGN-703
  • 末梢神經病變·ALS (肌肉萎縮性側索硬化症(俗稱漸凍人)) 轉動小分子
  • SPI-205
  • VBY-036

化療誘發性末梢神經病變治療藥:開發中產品的最新趨勢

化療誘發性末梢神經病變治療藥:開發暫停的產品

化療誘發性末梢神經病變治療藥:開發中止的產品

化療誘發性末梢神經病變相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿 (全6件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8395IDB

Summary

Global Markets Direct's, 'Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016', provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
  • The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects
  • The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chemotherapy Induced Peripheral Neuropathy Overview
  • Therapeutics Development
    • Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Overview
    • Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Development by Companies
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Chemotherapy Induced Peripheral Neuropathy - Products under Development by Companies
  • Chemotherapy Induced Peripheral Neuropathy - Products under Investigation by Universities/Institutes
  • Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
    • Achelios Therapeutics, Inc.
    • Advinus Therapeutics Ltd
    • Amplyx Pharmaceuticals, Inc.
    • Can-Fite BioPharma Ltd.
    • DermaXon, LLC
    • Eisai Co., Ltd.
    • Immune Pharmaceuticals Inc.
    • INSYS Therapeutics, Inc.
    • KPI Therapeutics, Inc.
    • Krenitsky Pharmaceuticals Inc.
    • Laboratorios Del Dr. Esteve S.A.
    • Lpath, Inc.
    • MAKScientific, LLC
    • Metys Pharmaceuticals AG
    • Midatech Pharma US Inc.
    • Nemus Bioscience, Inc.
    • Neurocentrx Pharma Ltd.
    • Panacea Pharmaceuticals, Inc.
    • PeriphaGen, Inc.
    • PharmatrophiX, Inc.
    • PledPharma AB
    • Sova Pharmaceuticals, Inc.
    • Spectrum Pharmaceuticals, Inc.
    • Virobay Inc.
    • WEX Pharmaceuticals Inc.
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amitriptyline + ketamine hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-1710 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AXPN-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BR-297 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dimiracetam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DX-0332 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-2072 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KP-544 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRN-5500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LM11A-31BHS - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lpathomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MR-309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-2111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NRX-2922 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-24336 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAN-811 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PGN-503 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piclidenoson - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pirenzepine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-095 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Q-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit FKBP52 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPI-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Tetrodotoxin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-036 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XT-150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
  • Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
  • Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
    • Featured News & Press Releases
      • Jun 02, 2016: NEMUS Bioscience Identifies Unique Cannabidiol Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program
      • Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA
      • Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program
      • Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA
      • Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation
      • Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2016
  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon, LLC, H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co., Ltd., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Lpath, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific, LLC, H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neurocentrx Pharma Ltd., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc., H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2016
  • Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2016
  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top